Effective today, Biogen Idec is known simply as Biogen. The company has introduced a new corporate identity and logo that reflect both its evolution and focus on bringing forth new therapies in areas of high unmet needs.
Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.
Government health advisers say a once-a-day respiratory inhaler from GlaxoSmithKline appears safe and effective for adults with asthma, but not for adolescents.
When Texas officials launched a massive public high school steroids testing program over fears of rampant doping from the football fields to the tennis courts, they promised a model program for the rest of the country to follow. But almost no one did.
More than half of the undergraduates at the University of Oregon have not been vaccinated against meningitis, despite the fact that one student has died and five others have been sickened since January.
In a delay that some say may have cost lives, the World Health Organization resisted calling the Ebola outbreak in West Africa a public health emergency until last summer, two months after staff raised the possibility and long after a senior manager called for a drastic change in strategy.
Coronado Biosciences has announced the formation of a new company, Mustang Therapeutics, Inc. Mustang will initially focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology.
Biogen Idec released much anticipated results from a study of a potential Alzheimer's disease treatment on Friday, showing that it slowed cognitive decline in some patients.
Evotec AG today announced that a definitive agreement for a major multi-component strategic alliance over the next five years has been signed with Sanofi. The transaction is expected to close on 31 March 2015.
Mergers and acquisitions in the pharmaceutical and biotechnology sectors set a record in 2014, according to a report by Evaluate Ltd.
Improved coordination between researchers and pharmaceutical companies could help bolster development of treatments for neurodegenerative diseases such as Alzheimer's or Parkinson's, according to an industry analyst.
An uncharacteristic joint effort by House Speaker John Boehner and his usual nemesis, Minority Leader Nancy Pelosi, to resolve a gnawing problem about how Medicare pays doctors underscores the political victories each sees in finally sweeping the issue off the deck — if they can.
A huge study of Pfizer's blockbuster vaccine against pneumonia and other bacterial infections in adults 65 and older found it protected most of them against dangerous infections in the bloodstream and other sterile body areas.
Under the terms of the agreement, Daiichi Sankyo will pay a $200M up-front fee and subsequent sales-related payments of up to $625M. AstraZeneca will be responsible for manufacturing, will book all sales and will make sales-related commission payments to Daiichi Sankyo.
The analysis by New York-based GBI Research predicted the recent expiration of patents for several of the top current therapeutics--most notably Singulair, Advair and Symbicort--would allow generic versions to curb market growth.